Please enter the number of seats you would like to purchase for this event and click the add to cart button to continue to the checkout process.
Based on our Pharmacor
Venous Thromboembolism advisory service, Decision Resources is offering an exclusive analyst call entitled
Venous Thromboembolism: How Will Sanofi-Aventis’s Semuloparin (AVE-5026) Compete in a Market That Will Soon Feature a Range of Oral Anticoagulants? Because this presentation features major updates, it is
ONLY available to purchasers of this Pharmacor advisory service.
Recorded live on Monday, July 26, 2010
This 15-minute analyst call, presented by Decision Resources Analyst Matthew Killeen, Ph.D., answers the following questions:
- In a market that will soon feature a range of oral anticoagulants, how can semuloparin compete against these therapies and gain traction in the market?
- As ongoing Phase III trials of semuloparin examine the drug in specific patient populations, what levels of competition from current and emerging therapies could semuloparin face in these indications?
- What challenges remain for the continued clinical development of semuloparin?
Contact us to learn how you can purchase this service and access a recorded playback of this event.
Click here to view the invite.